On Tuesday, NeoGenomics received a positive adjustment to its Relative Strength (RS) Rating, from 69 to 75.
IBD's unique RS Rating identifies technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History shows that the best-performing stocks often have an RS Rating of over 80 as they begin their largest price moves. See if NeoGenomics can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
NeoGenomics is building a consolidation with a 21.22 buy point. See if it can clear the breakout price in volume at least 40% higher than normal.
The company showed 0% EPS growth in the latest quarterly report. Sales gains came in at 10%.
The company holds the No. 5 rank among its peers in the Medical-Services industry group. Hims & Hers Health is the No. 1-ranked stock within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
